Tatva Chintan Pharma IPO will open for subscription from 16 July 2021. the company aims for an issue size of ₹500 Crore through this IPO.
Tatva Chintan Pharma Chem Limited
Incorporated in 1996, Tatva Chintan Pharma Chem Limited is a chemical manufacturing company that manufactures structure-directing agents (SDAs), phase transfer catalyst (PTCs), pharmaceutical and agrochemical intermediates, and other specialty chemicals. It is among the largest manufacturer of SDAs for zeolites in India.
The company serves customers across industries i.e. automotive, petroleum, agrochemicals, dyes and pigments, paints and coatings, pharmaceutical, personal care, and others. Its products are not only sold in India but also export to 25+ countries all over the world such as the USA, Germany, South Africa, China, and the UK. In FY 2020, total export contributed to 76% of total revenue from operations.
Merck, Bayer AG, Ipox Chemicals, Laurus labs, Navin Fluorine International Limited, Atul Limited, Otsuka Chemicals, SRF Limited, Hawks Chemical Company, Firmenich Aromatics Prod Pvt Ltd, and Divi’s laboratories are a few of customers of the company. Currently, it has two manufacturing facilities at Ankleshwar and Dahej in Gujarat.
Objects of the Issue
- Funding capital expenditures requirements for expansion of Dahej manufacturing facility.
- To meet general corporate purposes.
- Funding capital expenditures requirements to upgrade R&D facilities in Vadodara.
- Leading manufacturer of structure-directing agents and phase transfer catalysts.
- Diversified product portfolio.
- Global market presence with a customer base across industries.
- Strategically located manufacturing facility in Gujarat with close proximity to Hazira Port.
- Experienced promoters and managers team.
- Strong financial performance track record.
Basic details about the company
|Full name||Tatva Chintan Pharma Chem Ltd|
Dates to remember
|IPO Open||16 July 2021|
|IPO Close||20 July 2021|
|Basis of Allotment||26 July 2021|
|Refunds date||27 July 2021|
|Credit to Demat Account||28 July 2021|
|Listing Date||29 July 2021|
|Issue type||Book Building|
|IPO issue size||₹500 Crore|
|Fresh Issue||₹225 Cr|
|Offer for sale||₹275 Cr|
|Face value||₹10 Per Equity Share|
|Price band||₹1073 to ₹1083 per equity share|
|Lot size||13 Shares|
|Minimum application||1 Lot–13 Shares|
|Maximum application||13 Lots-182|
|Minimum application amount||₹14,079|
|Maximum application amount||₹197,106|
|Listing Exchange||BSE & NSE|
|Particulars||For the year/period ended (₹ in million)|
|Profit After Tax||522.62||377.89||205.43|
Valuation of Tatva Chintan Pharma (as of FY2020)
|Earnings Per Share (EPS)||₹26.02|
|Price/Earnings (PE ratio)||41.24 – 41.62|
|Return on Net Worth (RONW)||31.49%|
|Net Asset Value (NAV)||₹82.62 per share|
- Ajaykumar Mansukhlal Patel
- Chintan Nitinkumar Shah
- Snehkar Rasiklal Somani
- ICICI Securities Limited
- JM Financial Consultants Private Limited
Registrar of Tatva Chintan Pharma IPO
Link Intime India Private Limited C-101, 1st Floor,
247 Park Lal Bahadur Shastri Marg,
Vikhroli (West) Mumbai – 400 083
Phone: +91 22 4918 6200
Fax: +91 22 4918 6195
Tatva Chintan Pharma Contact Details
Tatva Chintan Pharma Chem Limited
Plot No. 353, Makarpura GIDC,
Vadodara, Gujarat – 390 010
Phone: +91 75748 48533
Tatva Chintan Pharma IPO Allotment Status
Tatva Chintan Pharma IPO allotment status will be available on Link Intime’s website.
Click on this link to get allotment status.
Tatva Chintan Pharma IPO is going to hit Dalal street soon. applying for IPO is purely a personal choice. study well about the company and do subscribe if you are feeling good about the company. I hope this post will give you enough details to make a fundamental study of the company. learn well and make a wise decision.